Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort
…, E Faure, J Poissy, C Chidiac, F Raffi… - Proceedings of the …, 2021 - National Acad Sciences
The characterization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral
kinetics in hospitalized patients and its association with mortality is unknown. We analyzed …
kinetics in hospitalized patients and its association with mortality is unknown. We analyzed …
[HTML][HTML] On-demand preexposure prophylaxis in men at high risk for HIV-1 infection
…, JM Le Gall, E Cua, A Pasquet, F Raffi… - … England Journal of …, 2015 - Mass Medical Soc
Background Antiretroviral preexposure prophylaxis has been shown to reduce the risk of
human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting results …
human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting results …
[HTML][HTML] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3 …
…, L Piroth, V Pourcher, JP Quenot, F Raffi… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
[HTML][HTML] Utility of hyposmia and hypogeusia for the diagnosis of COVID-19
…, J Jenvrin, R Lecomte, M Lefebvre, F Raffi - The Lancet Infectious …, 2020 - thelancet.com
1 Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N
Engl J Med 2020; published online Feb 28. DOI: 10.1056/NEJMoa2002032. 2 Hopkins C, …
Engl J Med 2020; published online Feb 28. DOI: 10.1056/NEJMoa2002032. 2 Hopkins C, …
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
…, A Minello, I Rosa, M Gelu-Simeon, I Portal, F Raffi… - The Lancet, 2019 - thelancet.com
Background Although direct-acting antivirals have been used extensively to treat patients
with chronic hepatitis C virus (HCV) infection, their clinical effectiveness has not been well …
with chronic hepatitis C virus (HCV) infection, their clinical effectiveness has not been well …
[HTML][HTML] Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy …
…, A Clarke, J del Romero Guerrero, F Raffi… - The Lancet, 2019 - thelancet.com
Background The level of evidence for HIV transmission risk through condomless sex in
serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral …
serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral …
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING …
F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti… - The Lancet, 2013 - thelancet.com
Background Dolutegravir (S/GSK1349572) is a once-daily HIV integrase inhibitor with
potent antiviral activity and a favourable safety profile. We compared dolutegravir with HIV …
potent antiviral activity and a favourable safety profile. We compared dolutegravir with HIV …
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double …
F Raffi, H Jaeger, E Quiros-Roldan… - The Lancet infectious …, 2013 - thelancet.com
Background In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior
efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for …
efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for …
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population
…, J Reynes, A Bingham, F Raffi… - Clinical infectious …, 2003 - academic.oup.com
The distribution of risk factors for cardiovascular disease in patients aged 35–44 years who
were treated for human immunodeficiency virus type 1 (HIV-1) infection was compared with …
were treated for human immunodeficiency virus type 1 (HIV-1) infection was compared with …
[HTML][HTML] Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors
…, G Gautier, P Gicquel, D Boutoille, F Raffi… - Journal of thrombosis …, 2020 - Springer
Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic
events are debated and highly heterogeneous. The objective was to determine incidence and …
events are debated and highly heterogeneous. The objective was to determine incidence and …